Recombinant DNA Advisory, Committee regulatory update

The RAC met to consider a plan to eliminate its overlap with the FDA on gene therapy trials. The plan proposed that all gene therapy protocols be submitted directly to the FDA, which would determine the submission format.

The Points to Consider establish the criteria for review of a proposed protocol. ...